It's concluded that EAM-2201 has the likely to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP3A4 and UGT1A3, and it is evaluated in pooled human liver microsomes. The testing stage features a comparison in between the ab initio structural energies and people predicted via the possible. This